Education
About Us
Working with TipRanks
Follow Us
Ovid Therapeutics (OVID)
:OVID
OVID Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.30 - $3.45
Previous CloseN/A
Volume22.63K
Average Volume (3M)388.28K
Market Cap
$21.42M
Enterprise Value$27.98M
Total Cash (Recent Filing)-$69.94M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.84
Next Earnings
May 08, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding71,075,005
10 Day Avg. Volume579,809
30 Day Avg. Volume388,277
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)53.38
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit49.44
Enterprise Value/Ebitda-0.46
Forecast
1Y Price Target
$3.25Price Target Upside1060.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Ovid Therapeutics News
PremiumCompany Announcements
Ovid Therapeutics Advances Pipeline Amid Financial Progress
---
Bulls Say, Bears Say
Bulls Say
Pipeline DevelopmentOvid Therapeutics has reprioritized its pipeline development efforts to focus more on the earlier-stage assets OV329 and OV350, while also preparing for the entry into the clinic of another candidate, OV4071.
Research And DevelopmentOV350 is the first candidate emerging from Ovid’s novel portfolio of KCC2 direct activators, exhibiting 100-1,000-fold higher potency for KCC2 compared to other peripheral K/Cs and NKCC1, limiting peripheral side effects.
Bears Say
Enterprise ValueOvid currently trades at a negative enterprise value and is slated to deliver multiple potential value inflection points over the course of the next 12-15 months.
Valuation AssumptionsAnalysts revise some of the valuation assumptions, including reducing the probability of approval for OV888 to 15% from the prior 20%.
---
Ownership Overview
9.63% Insiders
7.81% Mutual Funds
43.39% Other Institutional Investors
31.35% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OVID FAQ
What was Ovid Therapeutics’s price range in the past 12 months?
Ovid Therapeutics lowest stock price was $0.30 and its highest was $3.45 in the past 12 months.
What is Ovid Therapeutics’s market cap?
Ovid Therapeutics’s market cap is $21.42M.
When is Ovid Therapeutics’s upcoming earnings report date?
Ovid Therapeutics’s upcoming earnings report date is May 08, 2025 which is in 33 days.
How were Ovid Therapeutics’s earnings last quarter?
Ovid Therapeutics released its earnings results on Mar 11, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.169 by $0.039.
Is Ovid Therapeutics overvalued?
According to Wall Street analysts Ovid Therapeutics’s price is currently Undervalued.
Does Ovid Therapeutics pay dividends?
Ovid Therapeutics does not currently pay dividends.
What is Ovid Therapeutics’s EPS estimate?
Ovid Therapeutics’s EPS estimate is -0.14.
How many shares outstanding does Ovid Therapeutics have?
Ovid Therapeutics has 71,075,005 shares outstanding.
What happened to Ovid Therapeutics’s price movement after its last earnings report?
Ovid Therapeutics reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.169. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ovid Therapeutics?
Currently, no hedge funds are holding shares in OVID
---
Ovid Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.25 (1060.71% Upside)
$3.25 (1060.71% Upside)
Blogger Sentiment
Neutral
OVID Sentiment 50%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $5.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.0%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.78%
12-Months-Change
Fundamentals
Return on Equity
-33.88%
Trailing 12-Months
Asset Growth
-36.01%
Trailing 12-Months
Company Description
Ovid Therapeutics
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
---
OVID Stock 12 Month Forecast
Average Price Target
$3.25
▲(1060.71% Upside)
Technical Analysis
Sarepta Therapeutics
―
Ultragenyx Pharmaceutical
―
Editas Medicine
―
Arvinas Holding Company
―
Boundless Bio Inc.
―
Best Analysts Covering OVID
1 Year
1 Year Success Rate
7/14 ratings generated profit
1 Year Average Return
+36.07%
reiterated a buy rating 5 months ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +36.07% per trade.
---